Trial Profile

Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study of TransCon TLR7/8 Agonist Alone or in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid Tumor Malignancies

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 11 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary) ; TransCon TLR7/8 Agonist (Primary)
Indications Anal cancer; Cervical cancer; Head and neck cancer; Malignant melanoma; Penile cancer; Solid tumours; Squamous cell cancer; Vulvovaginal cancer
Focus Adverse reactions; First in man; Therapeutic Use
Acronyms transcendIT-101
Sponsors Ascendis Pharma

05 Jun 2025 Planned primary completion date changed from 1 May 2025 to 1 Jan 2026.
30 Oct 2024 Status changed from recruiting to active, no longer recruiting.
07 Feb 2024 According to an Ascendis Pharma media release, clinical update from dose expansion cohort fourth quarter of 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com